Form 8-K - Current report:
SEC Accession No. 0001437402-25-000016
Filing Date
2025-10-30
Accepted
2025-10-30 16:09:10
Documents
15
Period of Report
2025-10-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ardx-20251030.htm   iXBRL 8-K 25242
2 EX-99.1 ardx-20250930xexhibit991.htm EX-99.1 115185
6 ardx-20251030_g1.jpg GRAPHIC 75659
7 picture1.jpg GRAPHIC 19078
  Complete submission text file 0001437402-25-000016.txt   481261

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20251030.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20251030_lab.xml EX-101.LAB 23451
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20251030_pre.xml EX-101.PRE 13581
17 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20251030_htm.xml XML 2795
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36485 | Film No.: 251435587
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)